Our patented monoclonal antibodies target various physical structures common to tumors or infected cells as a means to selectively target therapy and diagnostics, while sparing normal, healthy cells. Our most advanced research focus is on the development of therapeutic antibodies that specifically target and act upon features of cancer and viral infections, including the blood vessels feeding tumors, distinctive features in the central core of tumors and cells that have been infected with viruses. By targeting these features associated with disease, our agents have the potential for enhanced efficacy and safety compared to conventional approaches.

Our clinical-stage platform technologies include phosphatidylserine (PS)-targeting therapy for cancers and viral diseases and tumor necrosis therapy (TNT). We are pursuing three separate clinical programs in cancer and anti-viral indications with our lead PS-targeting candidate bavituximab and TNT candidate Cotara®. Both bavituximab and Cotara are currently in Phase II clinical development.